Cardiovascular Risk in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide

CONCLUSIONS: Patients treated with TAF had comparable risks of cardiovascular outcomes, defined as MACE, as patients treated with TDF.PMID:37981763 | DOI:10.3350/cmh.2023.0328

Source: Clinical and molecular hepatology - November 20, 2023 Category: Gastroenterology Authors: Hyeyeon Hong Won-Mook Choi Danbi Lee Ju Hyun Shim Kang Mo Kim Young-Suk Lim Han Chu Lee Jonggi Choi Source Type: research